{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=PhaseBio+Pharmaceuticals+Inc.",
    "query": {
      "sponsor": "PhaseBio Pharmaceuticals Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=PhaseBio+Pharmaceuticals+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T00:36:35.159Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01427257",
      "title": "Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Single Dose PB1023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-02",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2012-10-01",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01427257"
    },
    {
      "nct_id": "NCT02808585",
      "title": "Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "PB1046 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2016-06",
      "completion_date": "2017-12-06",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 5,
      "location_summary": "Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "McKinney",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808585"
    },
    {
      "nct_id": "NCT02581657",
      "title": "Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "PE0139 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 37,
      "start_date": "2015-10",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2018-04-10",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 6,
      "location_summary": "Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581657"
    },
    {
      "nct_id": "NCT04433546",
      "title": "Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome",
        "Coronavirus",
        "Hypoxic Respiratory Failure",
        "Hypoxemic Respiratory Failure",
        "Respiratory Complication",
        "Respiratory Insufficiency",
        "Cardiac Dysfunction",
        "Pneumonia",
        "Pulmonary Edema",
        "Pulmonary Inflammation",
        "Respiratory Failure",
        "Cytokine Storm",
        "COVID 19",
        "SARS-CoV-2",
        "Cardiac Event",
        "Cardiac Complication",
        "Cardiac Failure",
        "Cardiac Infarct"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046)",
          "type": "DRUG"
        },
        {
          "name": "Low Dose (10 mg) Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 54,
      "start_date": "2020-07-15",
      "completion_date": "2020-12-02",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433546"
    },
    {
      "nct_id": "NCT01873885",
      "title": "Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo Single IV (Intravenous) Infusion",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Single IV Infusion Vasomera (PB1046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873885"
    },
    {
      "nct_id": "NCT01658501",
      "title": "Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "50 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "70 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "100 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "Placebo (0.9% Sodium Chloride)",
          "type": "DRUG"
        },
        {
          "name": "Victoza®",
          "type": "DRUG"
        },
        {
          "name": "Diet and Exercise",
          "type": "OTHER"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        },
        {
          "name": "Metformin and Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 593,
      "start_date": "2012-07",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 93,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658501"
    },
    {
      "nct_id": "NCT01478399",
      "title": "Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "PB1023 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-12",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2013-04-15",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 2,
      "location_summary": "Saint Paul, Minnesota • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01478399"
    },
    {
      "nct_id": "NCT01835730",
      "title": "Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "PE0139 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2013-04",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 3,
      "location_summary": "Anniston, Alabama • Hialeah, Florida • Renton, Washington",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01835730"
    },
    {
      "nct_id": "NCT03795428",
      "title": "Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046) Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-04-10",
      "completion_date": "2022-01-11",
      "has_results": false,
      "last_update_posted_date": "2022-02-22",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 16,
      "location_summary": "La Jolla, California • Sacramento, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03795428"
    },
    {
      "nct_id": "NCT03556020",
      "title": "Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 35,
      "start_date": "2018-07-15",
      "completion_date": "2022-01-07",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-10-01T00:36:35.159Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03556020"
    }
  ]
}